The WST-8 market is primarily divided by application, which accounts for the bulk of revenue generation. Cell viability assay represents the largest share, approximately 40 % of total sales, driven by its widespread adoption in pharmaceutical R&D, academic labs, and contract research organizations for quantifying proliferative capacity of adherent and suspension cells. Cytotoxicity testing follows with roughly 30 % of the market, reflecting demand from toxicology screening programs that require reliable, colorimetric readouts to assess compound‑induced cell death. Enzyme activity measurement contributes about 15 % as WST-8 serves as an electron acceptor in dehydrogenase‑linked assays, enabling kinetic studies of metabolic enzymes. The remaining 15 % is captured by high‑throughput screening (HTS) platforms, where the reagent’s rapid, homogeneous format supports miniaturized 384‑ and 1536‑well formats. Collectively, these application segments define the overall market size and are illustrated in the accompanying pie chart, underscoring the central role of WST-8 segmentation in market taxonomy. These proportions also reflect regional adoption patterns, with North America and Asia‑Pacific driving the bulk of cell‑viability purchases, while Europe shows higher penetration in HTS applications.
